Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity?
Year: 2018
Type: article
Study design: Observational Study
Abstract: Background Positron emission tomography (PET) studies in major depressive disorder (MDD) have reported higher serotonin 1A (5-HT1A) autoreceptor binding in the raphe. In males, the difference is so large that it can potentially be used as the first biological marker for MDD. However, the raphe includes several nuclei, which project to different regions of the brain and spinal cord and may be differentially involved in disease. We aimed to identify 5-HT1A differences in individual raphe nuclei using PET in order to determine whether use of subnuclei would provide greater sensitivity and specificity of diagnosing MDD. Methods We identified individual nuclei using a hybrid set-level technique on an average [11C]-WAY100635 PET image derived from 52 healthy volunteers (HV). We delineated three nuclei: dorsal raphe nucleus (DRN), median raphe nucleus (MRN), and raphe magnus (RMg). An atlas image of these nuclei was created and nonlinearly warped to each subject (through an associated MRI) in a separate sample of 41 males (25 HV, 16 MDD) who underwent [11C]-WAY100635 PET. Results 5-HT1A binding was elevated in DRN in MDD (P < .01), and was not different in the RMg and MRN between groups. Receiver operating characteristic (ROC) curves showed that combining DRN and MRN produces highest sensitivity (94%) and specificity (84%) to identify MDD. Conclusion In agreement with postmortem studies, we found higher 5-HT1A autoreceptor binding in MDD selectively in the DRN. 5-HT1A autoreceptor binding in the combined DRN and MRN is a better biomarker for MDD than in the raphe as a whole.
Source: Depression and Anxiety
DOI: 10.1002/da.22721
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: American Foundation for Suicide Prevention, Bristol-Myers Squibb, Columbia University, National Alliance for Research on Schizophrenia and Depression, Georgia Clinical and Translational Science Alliance, Stony Brook University, National Institutes of Health, National Institute of Mental Health
Awards: G2218376656, G2669489993, In Vivo Neurochemistry and Electrophysiology of Bipolar Disorder and its Treatment, G432825825, G436494665, G650754896, Lithium's Molecular Mechanism of Action and the Pathology of Bipolar Disorders, Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand, G803016639, Biological Predictors of Response to Antidepressants
OpenAlex ID: W2793772385
